Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study

Suppressor of tumorigenicity 2 (ST-2) is a marker of cardiac remodeling and fibrosis that correlates with disease severity in patients with pulmonary arterial hypertension (PAH), and is thought to be a predictor of clinical worsening. We performed a post hoc analysis assessing ST-2 as a potential biomarker of likelihood of response in patients switching from phosphodiesterase type 5 inhibitors (PDE5i) to riociguat, and the association of ST-2 with REVEAL risk score (RRS) in the RESPITE study.

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: R.L. Benza, J.R. Klinger, H.A. Ghofrani, P. Jansa, E. Gr ünig, D. Vizza, M.M. Hoeper Tags: 214 Source Type: research